Selank Tuftsin-Derived Heptapeptide Mechanism: A Research Review of GABAergic Allosteric Modulation, Enkephalinase Inhibition, BDNF Upregulation and Immunomodulatory Signal Transduction

Reviewed by Peptide Insider Research Staff · Published November 2026 · 10 min read

The synthetic heptapeptide selank peptide (TP-7; sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro) occupies a distinctive position in regulatory peptide pharmacology as a tuftsin-derived compound engineered for enhanced metabolic stability and multi-target central nervous system activity. Unlike single-receptor ligands, Selank simultaneously modulates GABAergic neurotransmission, endogenous opioid tone, neurotrophic factor expression and cytokine signalling — a pharmacological profile that has sustained more than two decades of preclinical investigation across rodent behavioural, transcriptomic and immunological models [1][2]. This review examines the molecular identity, mechanistic pathways, and preclinical evidence base for Selank, with reference to its structural relatives including semax and selank combinations and the N-acetylated variant na selank. All information is presented strictly for research reference; not for human or veterinary use.

Tuftsin Derivation and the Pro-Gly-Pro Stability Cassette

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide released by enzymatic cleavage of the Fc domain of immunoglobulin G in the spleen [3]. It functions as a phagocytosis-stimulating factor, activating macrophages and neutrophils through interactions that include formyl peptide receptor family signalling. However, native tuftsin is rapidly degraded by serum aminopeptidases, limiting its half-life in biological preparations to minutes.

The design of Selank addressed this limitation through the C-terminal addition of the tripeptide Pro-Gly-Pro, a sequence derived from collagen degradation fragments known to resist carboxypeptidase attack [1][4]. This Pro-Gly-Pro cassette confers two pharmacokinetic advantages: (a) protection of the C-terminus from exopeptidase cleavage and (b) conformational constraint through the proline residues that reduces endopeptidase access to the core tuftsin backbone. The resulting heptapeptide retains the immunomodulatory recognition elements of tuftsin while achieving a biological half-life compatible with intranasal delivery in rodent experimental protocols [1][2].

GABAergic Allosteric Modulation: Transcriptomic and Binding Evidence

The anxiolytic profile of Selank in preclinical models — elevated plus maze, open field and unpredictable chronic mild stress (UCMS) paradigms — has been attributed primarily to its interaction with the GABAergic system [2][5][6]. Critically, Selank does not bind the benzodiazepine site directly. Radioligand-receptor analyses using [³H]GABA demonstrate that Selank functions as a positive allosteric modulator of the GABA-A receptor complex, enhancing GABA binding in a concentration-dependent and subunit-selective manner [7].

Transcriptomic profiling of the rat frontal cortex following intranasal Selank administration (300 μg/kg) revealed altered expression of 45 genes at 1 hour and 22 genes at 3 hours post-administration [5]. Affected transcripts include GABA-A receptor subunits (Gabra2, Gabrb1, Gabrg2), the GABA transporter Slc6a11 (GAT-3), and multiple ion channel genes. Importantly, the gene expression profile induced by Selank correlates positively with the profile induced by GABA itself, supporting the conclusion that the peptide enhances inhibitory tone through the same transcriptional programmes activated by the endogenous neurotransmitter [5].

A subsequent study confirmed that Selank, GABA and the atypical antipsychotic olanzapine produce overlapping but non-identical transcriptomic signatures in frontal cortex tissue [8]. Selank partially blocked the modulatory activity of diazepam at GABA-A receptors, indicating that while their binding sites are not identical, they share structural proximity within the receptor complex [7][8]. This mechanistic distinction is consistent with the observation that Selank produces anxiolytic effects in rodent models without the sedation, ataxia, or dependence-like behaviours associated with classical benzodiazepine agonists [6][7].

Enkephalinase Inhibition and Endogenous Opioid Tone

A parallel mechanism contributing to Selank's behavioural profile is the inhibition of enkephalin-degrading enzymes. Specifically, Selank has been shown to inhibit aminopeptidase N (APN; CD13) and dipeptidyl peptidase-IV (DPP-IV) in serum and tissue preparations [9][10]. These peptidases are responsible for the rapid hydrolysis of endogenous Leu-enkephalin and Met-enkephalin — opioid pentapeptides that modulate pain perception, stress reactivity and reward circuitry through δ- and μ-opioid receptor signalling.

By stabilising endogenous enkephalin pools, Selank indirectly potentiates opioid tone without requiring direct binding to opioid receptors [9]. This indirect mechanism is supported by naloxone-antagonism experiments: the anxiolytic effects of Selank in certain behavioural paradigms are partially reversed by naloxone pretreatment, confirming that the opioid system participates in, but does not solely mediate, the compound's behavioural output [10]. Research in alcohol withdrawal models further demonstrated that Selank attenuated aversive signs of morphine withdrawal in rats, an effect consistent with enkephalin stabilisation [11].

BDNF Upregulation and Neuroprotective Signalling

Brain-derived neurotrophic factor (BDNF) is a critical regulator of synaptic plasticity, neuronal survival and memory consolidation. Selank administration has been reported to increase BDNF mRNA and protein levels in the hippocampus and prefrontal cortex of rats subjected to acute restraint stress and ethanol-induced memory impairment [12]. In the ethanol model, Selank prevented the suppression of hippocampal BDNF that typically accompanies ethanol exposure, and this rescue correlated with improved performance in passive avoidance memory tasks [12].

The BDNF-upregulating activity of Selank is distinct from, but complementary to, its GABAergic modulation. While GABA-A allosteric enhancement provides acute anxiolytic signalling, BDNF upregulation may support longer-term adaptive plasticity in circuits governing memory and emotional regulation. This dual-pathway profile — acute neurotransmission modulation combined with neurotrophic factor engagement — distinguishes Selank from both classical benzodiazepines (which lack BDNF effects) and from peptide compounds such as semax selank peptide combinations, where Semax primarily engages melanocortin receptor pathways rather than GABAergic modulation [5][12][13].

Immunomodulatory Activity: The Tuftsin Heritage

Selank's derivation from tuftsin — a fragment of the immunoglobulin G heavy chain — endows the heptapeptide with innate immune regulatory properties that extend beyond central nervous system effects. Transcriptomic analyses of mouse spleen tissue following Selank administration revealed significant alterations in the expression of genes encoding chemokines, cytokines and their receptors, including modulation of IL-6 expression and shifts in Th1/Th2 cytokine balance [14][15].

In the hippocampus and spleen, chronic Selank administration produced distinct but convergent transcriptomic signatures: inflammation-related gene expression showed a dynamic temporal profile with early upregulation followed by normalisation, suggesting a homeostatic regulatory mechanism rather than simple immunostimulation or immunosuppression [15][16]. Antiviral activity was demonstrated in a murine influenza model, where Selank reduced viral titre and modulated interferon-related gene expression [17]. These immunomodulatory findings are consistent with the tuftsin pharmacophore's known macrophage-activating properties and distinguish Selank from purely CNS-targeted anxiolytics.

Preclinical Evidence Table

Structural Variants: NA-Selank and the Semax–Selank Axis

The catalogue nomenclature surrounding Selank includes several structural and combinatorial variants that researchers should distinguish:

• NA-Selank (na selank peptide): The N-acetylated form of Selank, in which an acetyl group attached to the N-terminal threonine provides additional protection against aminopeptidase degradation. This modification is analogous to the N-acetylation strategy used in NA-Semax (N-Acetyl-Semax-Amidate) and is studied in comparative pharmacokinetic preparations [2].
• Semax and Selank: These two regulatory peptides are frequently co-referenced in research catalogues. Semax (ACTH(4-10)-Pro-Gly-Pro) shares the same Pro-Gly-Pro stability cassette but derives from a different parent molecule (adrenocorticotrophic hormone fragment). A selank semax blend appears in some catalogue listings but the compounds act through mechanistically distinct receptor systems — melanocortin (Semax) versus GABAergic/enkephalinergic (Selank) [5][13].
• Selank peptide bodybuilding references in search nomenclature reflect catalogue cross-contamination with performance-oriented queries; Selank has not been investigated as an anabolic or ergogenic agent in the published preclinical literature and such characterisation is not supported by the evidence base [2].

Frequently Asked Questions

What is selank peptide?

Selank peptide (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived from the endogenous immunomodulatory tetrapeptide tuftsin by addition of a C-terminal Pro-Gly-Pro stability cassette. It is studied in preclinical models for anxiolytic, nootropic and immunomodulatory properties [1][2]. This information is strictly for research reference; not for human or veterinary use.

What does selank peptide do in research models?

In preclinical research, selank peptide has been observed to function as a positive allosteric modulator of GABA-A receptors, inhibit enkephalin-degrading enzymes (aminopeptidase N and DPP-IV), upregulate BDNF expression in hippocampus and prefrontal cortex, and modulate cytokine expression including IL-6 [5][7][9][12]. These multi-target activities are investigated in rodent models of anxiety, memory impairment and immune modulation. This compound is for laboratory investigation only.

How does selank compare with semax?

Semax and selank are both synthetic regulatory peptides developed from endogenous precursors. Selank derives from tuftsin (immunoglobulin G fragment) and is primarily studied for anxiolytic and immunomodulatory activity via GABAergic modulation, whereas Semax derives from ACTH(4-10) and engages melanocortin receptor pathways for neuroprotective effects [5][13]. A selank semax blend is referenced in catalogue nomenclature but each compound acts through distinct receptor systems. Research-use only.

What is NA-Selank?

NA selank (N-Acetyl-Selank) is the N-acetylated structural variant of Selank, in which an acetyl group protects the N-terminal threonine from aminopeptidase degradation. This modification is designed to extend the biological half-life of the parent compound in research preparations [2]. Na selank peptide is studied alongside the parent compound in comparative pharmacokinetic assays. For research use only; not for human or veterinary administration.

Where to Source for Research

Researchers requiring Selank (TP-7) reference material should verify certificate-of-analysis documentation confirming sequence identity and peptide purity (≥ 98 % by HPLC). Suppliers currently listing Selank for research-use-only purchase include Short Chain Aminos as a primary catalogue source, alongside BioPep, Catalyst Research and Apex Research Services. No supplier has been assessed or endorsed by this publication; researchers should independently verify purity, identity and regulatory compliance for their jurisdiction.

Works Cited

1. Siebert A, Gensicka-Kowalewska M, Cholewinski G, Ostrowska K. Tuftsin - Properties and Analogs. Curr Med Chem. 2017;24(44):4808-4839. PMID: 28745220.
2. Vyunova TV, Andreeva LA, Shevchenko KV, Shevchenko VP, Bobrov MYu, Myasoedov NF. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. PMID: 30255741.
3. Najjar VA, Nishioka K. "Tuftsin": a natural phagocytosis stimulating peptide. Nature. 1970;228(5272):672-673. PMID: 4097539.
4. Andreeva LA, Myasoedov NF. Ex vivo screening of prospective peptide drugs: new approaches. Bull Exp Biol Med. 2010;150(1):1-4. PMID: 20963648.
5. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26924987.
6. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. PMID: 28280289.
7. Povarov IS, Bhave SP, Bhave SV, et al. Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons. Bull Exp Biol Med. 2017;163(1):64-67. PMID: 28361410.
8. Filatova E, Shadrina M, Slominsky P, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2017;8:89. PMID: 28293190.
9. Zozulia AA, Kost NV, Sokolov OIu, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096.
10. Kozlovskiĭ II, Danchev ND, Zhiliaev SIu. [The role of opioid system in peculiarities of anti-anxiety effect of peptide anxiolytic selank]. Eksp Klin Farmakol. 2012;75(2):15-17. PMID: 22550852.
11. Konstantinopolsky MA, Chernyakova IV, Kolik LG. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;174(2):218-222. PMID: 36322304.
12. Kolik LG, Nadorova AV, Gudasheva TA. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus. Bull Exp Biol Med. 2019;167(5):641-644. PMID: 31625062.
13. Slominsky PA, Shadrina MI, Kolomin TA, et al. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Dokl Biol Sci. 2017;474(1):106-109. PMID: 28702721.
14. Kolomin T, Shadrina M, Slominsky P, et al. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18-23. PMID: 21609736.
15. Kolomin T, Shadrina M, Slominsky P, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50-57. PMID: 24291245.
16. Kolomin TA, Shadrina MI, Aguiiar Diaz YhL, et al. [Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank]. Mol Biol (Mosk). 2013;47(3):500-508. PMID: 24450168.
17. Ershov FI, Uchakin PN, Uchakina ON, et al. [Antiviral activity of immunomodulator Selank in experimental influenza infection]. Vopr Virusol. 2009;54(5):19-24. PMID: 19882898.

This article is provided strictly for research reference; not for human or veterinary use. Peptide Insider does not endorse, recommend or provide guidance on the administration of any compound to humans or animals. Investigators should consult applicable institutional and regulatory guidelines before initiating any research protocol.